Tradestie Institutional Equity Comparison Engine
CLBR vs BGLC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BGLC Overall Edge
BGLC Captures Institutional Edge (1โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioNexus Gene Lab Corp Common stock (BGLC) driven by superior Growth & Margin while CLBR counters with relative strength in Momentum & Technical. Fundamentally, CLBR trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus BGLC at N/M Forward P/E and -88.2% operating margin (-96.6% YoY). In options structure, CLBR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BGLC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CLBR N/M vs BGLC N/M Fwd P/E
Growth & Margin Winner
BGLC
Op Margin N/A vs -88.2% ยท YoY N/A vs -96.6%
Momentum & Technical Winner
CLBR
1Y -0.5% vs -85.0% ยท 52W Pos 5% vs 1%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLBR
US Equity
CLBR
Institutional Equity
$10.02
-0.1% 1D
Market Cap
N/A
1M Return
-0.4%
1Y Return
-0.5%
Forward P/E
N/M
Unified AI Score
47.5 / 100
HOLD
Tech 50.0
Fund 54.0
Flow 50.0
Mom 64.0
BGLC
NASDAQ
BioNexus Gene Lab Corp Common stock
Services-Medical Laboratories
$0.68
+0.0% 1D
Market Cap
$2.0M
1M Return
-42.86%
1Y Return
-84.99%
Forward P/E
N/M
Unified AI Score
44.2 / 100
HOLD
Tech 45.0
Fund 42.0
Flow 50.0
Mom 63.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CLBR -0.5%
BGLC -84.99%
Spread: +70.54 pp (CLBR Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CLBR TTM Op. Margin: N/A
BGLC TTM Op. Margin: -88.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLBR vs BGLC. Trailing 12-month operating profitability (CLBR N/A vs BGLC -88.2%) and valuation multiples (CLBR N/M vs BGLC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CLBR | BGLC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $2.0M | Larger Scale | BGLC |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | -96.6% | Higher Growth | BGLC |
| Operating Margin (TTM) Profitability | N/A | -88.2% | Higher Margin | BGLC |
| Net Profit Margin Profitability | N/A | -82.4% | Higher Margin | BGLC |
| Return on Equity (ROE) Capital Efficiency | N/A | -33.7% | Higher ROE | BGLC |
| 52-Week Range Position Momentum | 5% ($10โ$10) | 1% ($1โ$5) | Stronger Trend | CLBR |
| Beta / 30D Volatility Risk Regime | 0.08ฮฒ ยท 4% Vol | 1.34ฮฒ ยท 86% Vol | Lower Realized Risk | CLBR |
| Unified Institutional Score Composite Signal | 47.5 / 100 (HOLD) | 44.2 / 100 (HOLD) | Higher Composite | CLBR |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CLBR vs BGLC Buy Guide
CLBR
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
BGLC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CLBR nor BGLC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.